Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA, Sophia Genetics Partner on Tumor Profiling

NEW YORK – OncoDNA announced Thursday that it is partnering with Sophia Genetics to improve analysis and interpretation of genomic profiles.

Gosselies, Belgium-based OncoDNA said that it will customize its OncoKDM genomic interpretation platform to work with Sophia's DDM genomic analytics technology. This, according to the companies, will automate analysis and translation of complex genomic data generated by DDM into actionable recommendations for individual tumor profiles.

"By collaborating with [Sophia], we will be able to leverage our combined scientific and technical knowledge in oncology to provide an even more comprehensive solution that will enable laboratories to integrate large-panel genomic profiling into their workflows and outsmart the molecular complexity of cancer independently," Jean-Pol Detiffe, OncoDNA's chief strategy and innovation officer, said in a statement.

"Combining OncoKDM with our intuitive Sophia DDM platform will further increase options for the interpretation of complex, high-volume genomic data to our global community and beyond," said Lara Hashimoto, chief business officer of Swiss-American firm Sophia. "This partnership will allow us to continue to deliver on the promise and push the boundaries of precision medicine, ultimately benefiting even more patients worldwide."

The firms named Lorraine Institute of Oncology in Nancy, France, as an early user of the combined technology.

"The addition of OncoKDM will further advance our capabilities and help us keep track of the latest cancer treatment options," said Alexandre Harlé, a professor at the French institute. "It will facilitate our routine work, enabling us to analyze an ever-growing panel of cancer-related genes rapidly, identify biomarker-associated drugs or clinical trials for more patients, and discuss complex cases through virtual meetings and tumor boards."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.